Financial Planning & Analysis Business Partner And become the key link between Finance and our Global Sales & Marketing teams.

SPINEART is a privately held medical device company based in Geneva, Switzerland, focused on simplifying the surgical act by designing, developing, and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients.

Selling in over 60 countries, Spineart is a pioneer in its field, having introduced unique technologies in the fields of Minimally Invasive Surgery, Motion Preservation, Fusion, Biologics and Fracture Treatment.

Spineart markets a complete portfolio combining traceable barcoded sterile packed implants with compact instrument sets, thus proudly promoting greater safety, cost-efficiency, and compliance at the hospital.

Our success also depends on our team’s value. The human being is at the centre of our concerns. We pay special attention to our recruitment to make Spineart a great place to work.

For us, soft skills are as important as hard skills. What we expect from our employees is nothing short of real team spirit, mutual assistance, and self-transcendence.

Our philosophy: Quality, Innovation, Simplicity

Our values: Respect, Integrity, Solution oriented

Do you want to work for an innovative specialist spinal implant company and play a pivotal role in helping us in new market opportunities and optimizing pricing strategies?

If yes, join our financial team as

Financial Planning & Analysis Business Partner

And become the key link between Finance and our Global Sales & Marketing teams.

Your main responsibilities will be:

• Commercial Partnership: Act as the primary finance lead for our European commercial teams. You are their "go-to" for financial clarity. Ensure alignment between commercial objectives and financial performance targets.
• Business Case: Build robust financial models for new product launches, market expansions, and clinical trial investments. Perform scenario and sensitivity analysis, evaluate ROI and payback, and provide structured recommendations to support capital allocation.
• Profitability Management: Analyse gross margins and net profitability by region, product line, and distributor. Identify "leakage" and suggest corrective actions. Recommend and follow corrective actions to improve contribution margins and overall financial performance.
• Performance Tracking: Own the commercial KPI dashboard (Sales vs. Plan, ASP trends, Funnel conversion, Regional Financial statements) and provide the "why" behind the numbers. Support forecasting, re-forecasting, and performance reviews with senior management.
• Deal Desk Support: Evaluate complex commercial rebate structures, and tender offers to ensure we win business without sacrificing margins.

Your profile:

• 8 years in financial planning and analysis (FP&A), with a heavy focus on Commercial/Sales Finance.
• Prior experience in MedTech, Biotech, or Pharma is a significant plus to understand the nuances of healthcare reimbursement and global pricing.
• Advanced Excel skills are a given.
• Experience with BI tools (Excel, PowerBI) and ERP systems (D365, etc.) is highly valued
• Fluent in French and English, both are daily working language. You will be communicating daily with stakeholders in the USA and Europe; the ability to pivot between these languages and cultures is essential. Other European language would be an asset.
• Master’s Degree in Finance, Accounting, Economics, or Business Administration.
• Strong advisory mindset: You don’t just share financial insights or present data, you translate them into clear, meaningful guidance and you provide actionable recommendations
• Clarity in communication: You communicate EBITDA fluctuations with ease, adapting your message to diverse audiences and fostering understanding and alignment across non-finance stakeholders.
• Strong organizational and interpersonal skills

We look forward to receiving your application at

https://spineart.bamboohr.com/careers/103?source=aWQ9MTE=

Please note that only applications submitted through this link will be reviewed.